Navigation Links
IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results
Date:4/10/2008

06, an increase of 4.9%. Domestic sales contributed 58.1% of total ophthalmology revenues while international contributed 41.9%. Total domestic revenues were $18.8 million in 2007, an increase of 3.3% from 2006. Total international ophthalmology revenues were $13.6 million for the fiscal year 2007, an increase of 7.3% compared to 2006.

Ophthalmology recurring revenues, consisting of disposable products and service, which represented 48.6% of our total ophthalmology revenues in 2007, were up 13.7% from $13.8 million in 2006 to $15.7 million in 2007.

"Our ophthalmology franchise is a healthy and growing business," continued Mr. Boutacoff. "Our margins remain strong with approximately half of revenues being generated from recurring revenues. The therapeutic ophthalmology market, in which we participate, is also less influenced by recessionary pressures than those medical markets which are based upon primarily elective or private pay procedures."

Aesthetics

Total aesthetics revenues were $5.2 million in the fourth quarter of 2007 compared with $1.4 million in the comparable period of 2006, primarily because of the AMS/Laserscope acquisition. In the fourth quarter 2007 domestic aesthetics revenues increased $1.4 million to $2.3 million and international aesthetics revenues increased $2.5 million to $2.9 million.

Full year 2007 aesthetics revenues were $23.2 million compared with $5.1 million in 2006, primarily the result of the AMS/Laserscope aesthetics acquisition. Domestic aesthetics revenues were $11.1 million for the full year 2007, an increase of $7.5 million from 2006. International aesthetics revenues were $12.0 million for the full year 2007, an increase of $10.6 million compared to 2006.

"The AMS/Laserscope aesthetics acquisition has been challenging and our results have not matched our original expectations," continued Mr. Boutacoff. "This has culminated in a review of the value of goodwill and intangible assets created
'/>"/>

SOURCE IRIDEX Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. IRIDEX Announces Fourth Quarter and Full Year 2007 Conference Call and Release Date
2. IRIDEX Reports Third Quarter Financial Results
3. IRIDEX Announces Third Quarter 2007 Conference Call and Release Date
4. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
5. James B. Hawkins Appointed to IRIDEX Board of Directors
6. IRIDEX Appoints Burr, Pilger & Mayer New Independent Auditor
7. William Moore Appointed to IRIDEX Board of Directors
8. IRIDEX Announces Closing of $5.0 Million Private Placement
9. Haemacure Reports on its annual general and special meeting of shareholders
10. Obesity Costs U.S. Companies as Much as $45 Billion a Year, The Conference Board Reports
11. Consumer Reports: If Your Gums Could Speak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- Allscripts (Nasdaq: MDRX ) announced today ... the three and six months ended November 30, ... January 11, 2010. Allscripts management will host a ... earnings and other information at 8:30 AM Eastern ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second quarter ...
(Date:12/16/2009)... Dec. 16 The most widely used human embryonic ... raises social justice questions that must be addressed to ... cell advances, according to a University of Michigan research ... kind, the U-M team analyzed 47 embryonic stem cell ... stem cell researchers. The scientists determined the genetic ancestry ...
(Date:12/16/2009)... HealthSciences Institute will sponsor a ... teams and organizations who serve individuals at ... in employer, health plan, medical home and ... offer free, noncommercial webinars on topics, solutions ... management and care improvement. Each webinar will ...
(Date:12/16/2009)... susceptibility to disease , , WEDNESDAY, Dec. 16 (HealthDay ... to leprosy have been identified by scientists in ... more than 10,000 DNA samples from leprosy patients ... highlights the important role that the innate immune ... "Though leprosy is not common, the discoveries have ...
(Date:12/16/2009)... led by the Wellcome Trust Sanger Institute announce the ... cancers are caused by mutations in the DNA of ... The studies, of a malignant melanoma and a lung ... mutations in the genomes of two cancers. , Lung ... almost all are associated with smoking. The number of ...
Breaking Medicine News(10 mins):Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Leprosy Genes Identified 2Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6
... The risk of cardiovascular, muscular and skeletal defects is slightly ... in vitro fertilization (IVF) // when compared to those conceived ... finding would be valuable in the United States where nearly ... The study however fails to prove that IVF is the ...
... probably the highest paid star in the Indian film ... evening today. ,Mr.Bachhan who is 63, was first ... Mumbai's Lilavati Hospital on Monday following complaints of abdominal ... he was recovering well. According to one report he ...
... have transplanted almost half of face taken from a brain dead ... tissue from the lips, nose and chin was taken and transplanted ... dog. ,Doctors have clarified that the face the ... and not resemble the donor’s face. ,If accepted the ...
... the HIV virus by their husbands. South Asia has a ... for 5.1 million of this figure. ,The AIDS Epidemic ... new infections (in India) is occurring in women who are ... currently or in the past) frequented sex workers.' ,'HIV ...
... have succumbed to pneumonia in the earthquake affected areas ... severe cold in the earthquake-hit areas is reported to ... people. The inadequate medical facilities in the quake-hit areas ... ,'More than 30 people have been reported dead ...
... employees of the Suffolk East Primary Care Trust will be ... as they are wearing their identification// badge or uniform. The ... patients, contractors, visitors, volunteers and other people who visit the ... (PCT) combined board has been called upon to give its ...
Other Medicine News:Health News:Risk Of Birth Defects Slightly Increased Due To IVF 2Health News:Amitabh Bachchan - India’s Superstar Undergoes Surgery 2Health News:More Married Women In India Are Getting Infected By HIV 2Health News:Pneumonia Claims 30 Lives In Pakistan 2
(Date:12/16/2009)... Dec. 16 According to Millennium Research ... market intelligence, health care reforms in China supported ... in 2009, and will continue to fuel growth ... Asia Pacific Markets for Interventional Cardiology Devices 2010 ... Chinese government will allow the Chinese drug-eluting stent ...
(Date:12/16/2009)... -- Biovista Inc.,today announced that it was awarded ... the 2009 New England Venture Summit, held on ... cutting edge private companies,driving the future of innovation, ... other privately held companies that play a leading ... Clean-tech sectors. , "We ...
(Date:12/16/2009)... -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... products, today announced top-line efficacy and safety results ... for the treatment of Peyronie,s disease. Peyronie,s disease ... on the shaft of the penis, which can ... or impossible in advanced cases. The Phase 2b ...
Breaking Medicine Technology:Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Biovista Inc. Named Top Innovator in Life Sciences 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4No Link Found Between Birth Anesthesia and Learning Issues 53665 1No Link Found Between Birth Anesthesia and Learning Issues 53665 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 1Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 3Silenced genes as a warning sign of blood cancer 53655 1Silenced genes as a warning sign of blood cancer 53655 2
... study evaluating DUROS(R) continuous delivery of exenatide for the ... Intarcia Therapeutics, Inc. today announced the completion of patient ... 650 (DUROS(R) continuous delivery of exenatide). The study is ... and involves the treatment of 44 patients with type ...
... Trial Expected to Initiate in 2010 for BlinatumomabNEW YORK, ... ), a biopharmaceutical company developing novel, proprietary antibodies for ... held an R&D Day for investors and financial analysts ... The presentations highlighted significant areas of development across Micromet,s ...
Other Medicine Technology:Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4
... a heartbeat. The bodys warmth beneath drapes. ... vital signs are yours to guard, measure, ... Temperature Monitoring products helps you do your ... provide the most comfortable and precise management ...
... The pause of a heartbeat. The bodys ... rhythmic breathing. These vital signs are yours ... DeRoyals line of Temperature Monitoring products helps ... information needed to provide the most comfortable ...
... the breaking up of the membranes ... into an oily substance that is ... manner. The results give rise ... a short time, without the secondary ...
... the capability of emission at two different wavelengths ... ablative capacities.Smart 1064 DW is able to select ... 1064 nm (with powers selectable among 4 and ... 2 and 25 W). This second wavelength is ...
Medicine Products: